Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

Pasquale Mone, Angela Lombardi, Jessica Gambardella, Antonella Pansini, Gaetano Macina, Maria Morgante, Salvatore Frullone, Gaetano Santulli

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

OBJECTIVE To assess whether the sodium–glucose cotransporter 2 (SGLT2) inhibitor empagli-flozin improves cognitive impairment in frail older adults with diabetes and heart failure with preserved ejection fraction (HFpEF). RESEARCH DESIGN AND METHODS We designed a prospective study to assess cognitive and physical function in con-secutive frail older adults with diabetes and HFpEF, comparing the effects of empagliflozin, metformin, and insulin. RESULTS A total of 162 frail older adults with HFpEF and diabetes successfully completed the study. Montreal Cognitive Assessment scores at baseline and after 1 month were 19.80 ± 3.77 vs. 22.25 ± 3.27 (P < 0.001) in the empagliflozin group, 19.95 ± 3.81 vs. 20.71 ± 3.56 (P 5 0.26) in the metformin group, and 19.00 ± 3.71 vs. 19.1 ± 3.56 (P 5 0.81) in the insulin group. A multivariable regression analysis confirmed the beneficial effects of empagliflozin. Additionally, we observed a marked amelioration of physical impairment, assessed by the 5-m gait speed test, in the empagliflozin and metformin groups but not in the insulin group. CONCLUSIONS This study is the first to show significant beneficial effects of the SGLT2 inhibitor empagliflozin on cognitive and physical impairment in frail older adults with diabetes and HFpEF.

Original languageEnglish (US)
Pages (from-to)1247-1251
Number of pages5
JournalDiabetes care
Volume45
Issue number5
DOIs
StatePublished - May 2022

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Fingerprint

Dive into the research topics of 'Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction'. Together they form a unique fingerprint.

Cite this